Thread by @MPishvaian

#GI25 @ASCO
We're in that gap between the holidays🎄and GI-ASCO (if that matters to you😉)
➡️And, we're stuck here at home because of the snow🌨️ outside

📢So this is a perfect time to present my "Top Abstract Titles" that I will be looking out for🔍at ASCO GI

#GI25 @ASCO
Starting with #PancreaticCancer and Ras⛔️
Actually only2⃣titles I saw:
1⃣@GarridoLagunaMD🗣️ctDNA🩸changes in the Ph1 trial of the Ras(on)⛔️RMC-6236 Abs 722; Poster#H10

2⃣@AlexSpiraMDPhD🗣️a Ph1 trial of the G12D specific⛔️RMC-9805 Abs 724; Poster#H12

#GI25 @ASCO
Trials in #PancreaticCancer focused on HRD:
1⃣Dr. Kawamoto🗣️a Ph2 trial of nirap for BRCAm PDAC & BTC Abs 589; Post#C15
2⃣@PeterHoseinMD updates on Ipi-Nivo for BRCAm PDAC Abs 715; Post#H3
3⃣@kjazieh🗣️a Ph2 trial of nirap+dostarlimab for HRDdef PDAC Abs 727; Post#H15

#GI25 @ASCO
Two trials on the tissue factor⛔️, pamrevlumab (PAM) in #PancreaticCancer, both by Dr. Piccozzi:
1⃣LAPIS, a R-Ph3 trial of chemo +/- PAM for LAPC, Oral Abstract #675
2⃣The Precision Promise trial @PanCAN of PAM+gem/nab-pac for mPDAC, Oral Abstract # 673

#GI25 @ASCO
Other trials in #PancreaticCancer:
1⃣Dr. Liu🗣️aPh1b trial of FG-M108 in CLDN18.2+ PDAC, Abs 729, Post#H17
2⃣@EileenMOReilly🗣️the CD40 agonist, mitaz+FFX for mPDAC, Abs 723; Post#H11
3⃣Dr. Seufferlein🗣️the GOBLET study: pelareorep+FFX+atezo in mPDAC, Abs 730; Post#H18

#GI25 @ASCO
Finally, some interesting surgical🔪trials in #PancreaticCancer:
1⃣&2⃣Do we operate on PDAC with liver mets❓
Dr. Wei will🗣️this in Abs 714, Post#H2
Dr. Kim🗣️stratifying such patients, Abs 711, Post#G25
3⃣Dr. Li🗣️the QOL impact of surgery for PDAC, Abs 699, Post#G13

@ASCO #GI25 @ASCO
Next, #cholangiocarcinoma and there were a lot of very interesting titles here to watch out for, most in the realm of🎯💊
➡️But one big adjuvant trial to🔦is:
Dr. Atul Sharm🗣️a R-Ph3 trial of adj Chemo vs. Chemo☢️for gallbladder cancer (ACCELERATE trial), Oral Abs 519

@ASCO #GI25 @ASCO
Two abstracts🔦the importance of NGS🧬testing in #cholangiocarcinoma:
1⃣Dr. Zheng-Lin🗣️the Real-World impact of matched🎯💊on survival in advanced BTC, Abs 536, Post# A14
2⃣@HardingJJMD🗣️the Molecular & clinical determinants of🎯💊outcomes in BTC, Abs 555, Post# B7

@ASCO @HardingJJMD #GI25 @ASCO
3⃣abstracts🔬outcomes of Pts with specific🧬alterations in #cholangiocarcinoma:
1⃣&2⃣look at MDM2amp BTC:
➡️Dr. Iyer, Abs 544; Post#A22
➡️@MacarullaTeresa, Abs 615, Post#D16
3⃣Richard Kim🗣️Real-World OS in BTC Pts with IDH1mut or FGFR2fus + BTC, Abs 548; Post#A26

#GI25 @ASCO
Finally, two additional abstracts to watch for in #cholangiocarcinoma:
1⃣Dr. Priyanshi Shah🗣️Long-term outcomes for MSI-H BTC patients on immunotherapy, Abs 592; Post#C18
2⃣Dr. Christos Fountzilas🗣️🎯FGFR in the Ph2 trial of Tinengotinib for BTC Pts, Abs 608; Post#D9

@ASCO #GI25 @ASCO
For #colorectalcancer, there are many great abstracts-so this is just a few to🔦:
Pre-op:
1⃣@CQvortrup🗣️a Single-cycle of neoadj pembro for Stage I-III MMRdef CRC, Oral Abs 19
2⃣@jonathanloree🗣️using ctDNA🩸to support Non-Op management in rectal cancer, Oral Abs 20

@ASCO @CQvortrup @jonathanloree #GI25 @ASCO
The BIG trial in #colorectalcancer will be @skopetz 🗣️BREAKWATER, the 1st line R-Ph3 trial of encorafenib + cetuximab + chemotherapy in BRAF V600E-mutant met CRC, Oral Abs 16

@ASCO @CQvortrup @jonathanloree @skopetz #GI25 @ASCO
And 3 immunotherapy trials in #MCRC:
1⃣Thierry Andre🗣️the LBA of Ipi-Nivo vs Nivo of dMMR mCRC, ABS LBA143
2⃣ @mgfakih🗣️a Ph2 trial of BOT +/- Bal in MSS mCRC (no liver mets), Oral Abs 23
3⃣Joel R Hecht🗣️a Ph2 trial of a personalized Neo-Ant IO for MSS CRC, Abs LBA13

@ASCO @CQvortrup @jonathanloree @skopetz @mgfakih #GI25 @ASCO
Also many great UGI Ca trials. Here are a few that caught my👁️:
1⃣Dr. Yan🗣️a R-Ph3 trial of IP+IV vs IV taxol+S-1, Oral Abs 327
2⃣ Dr. Wong🗣️CRS-HIPEC for Gastric Ca, Oral Abstract: 328
3⃣Dr. Abe🗣️Rfs for Gastric Ca pts with peritoneal Dz, Abs 400; Post#D14

@ASCO @CQvortrup @jonathanloree @skopetz @mgfakih #GI25 @ASCO
Treatment of squamous cell esophageal cancer (SCC):
1⃣Dr. Leng🗣️a R-Ph3 trial of sintilimab+Chemo☢️ +/- chemotherapy as neoadj Tx for esophageal SCC, Abs LBA329
2⃣Dr. Qi Wang🗣️nimotuzumab+chemotherapy+IO as 1st-line Tx esophageal SCC, Abs 344

@ASCO @CQvortrup @jonathanloree @skopetz @mgfakih #GI25 @ASCO
Two neoadjuvant IO trials for MMRdef gastric cancer:
1⃣@sonbol_bassam🗣️NeoAdj IO and non-Op mgmt for MMR def GC, Abs 451; Post#F16
2⃣Dr. Kennedy🗣️a Ph2 trial of periOp pembro, Abs 441; Post#F6

@ASCO @CQvortrup @jonathanloree @skopetz @mgfakih @sonbol_bassam #GI25 @ASCO
Finally, 2 HER2-targeted trials in upperGI cancer:
1⃣@KoheiShitara🗣️ASPEN-06, a CD47-targeted immuncheckpoint inhibitor for HER2+ gastric cancer, Oral Abs 332, Post#C24
2⃣Dr. Frost🗣️a Ph1 trial of a HER2 directed CAR-T cell Tx, Abs 449, Post#F14

@ASCO @CQvortrup @jonathanloree @skopetz @mgfakih @sonbol_bassam @KoheiShitara #GI25 @ASCO
And rounding out the review with several HCC and neuroendocrine tumor abstracts to watch for:
➡️To wade into the debate of atezo-bev vs. durva-tremi as 1st line Tx for #HCC Dr. Kournoutas🗣️A Real World retrospective comparison of the two, Abs 532; Post#A10

@ASCO @CQvortrup @jonathanloree @skopetz @mgfakih @sonbol_bassam @KoheiShitara #GI25 @ASCO
There are several abstracts on IO+TACE/TARE, which I always find compelling:
1⃣Dr. Yan🗣️TACE+bev-atezo, Abs 542; Post# A20
2⃣Dr. Vogel🗣️IO + RFA, Abs 582; Post#C8
3⃣Dr. Kim🗣️TACE+PD-L1+CTLA-4 blockade, Abs 609, Post#D10
4⃣Dr. Grahovac🗣️TARE+IO, Abs 617, Post#D18

@ASCO @CQvortrup @jonathanloree @skopetz @mgfakih @sonbol_bassam @KoheiShitara #GI25 @ASCO
And for the last of my abstract reviews - Dr. Strossberg will present 2 abstracts for NET:
1⃣A Ph1b trial of RYZ101 GEP-NETs after 177Lu-Tx (ACTION-1), Abs 661; Post# F4
2⃣ICIs for NET Pts w/High TMB or MMRdef after Tx with alkylating agents, Abs 662; Post# F5

@ASCO @CQvortrup @jonathanloree @skopetz @mgfakih @sonbol_bassam @KoheiShitara #GI25 @ASCO

I hope you all found this list helpful - and I will be very curious to see how the selections hold up after the actual abstracts/presentations are reviewed

Hope to see you all in San Francisco!